Everest Medicines Advances APAC Growth Strategy with Bejescin Acquisition

Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd., under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China.

This collaboration will strengthen Everest Medicines' presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.

"We are delighted to collaborate with Mabworks on Bejescin. As the first CD20 antibody approved globally for NMOSD, Bejescin has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "This collaboration strengthens Everest's portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin^® across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines' presence in the Asia-Pacific and global innovative medicines market."

"We are thrilled to announce our partnership with Everest Medicines on Bejescin across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin possesses exceptional product competitiveness and market potential." said Mr. Luning Chen, President of Mabworks. "Since its launch in Mainland China, Bejescin has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin's commercial network and brand influence across the Asia-Pacific region, bringing 'New Hope' to more patients with renal and autoimmune diseases."